Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 15/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745885 | 0.80 | KDM4E (0.44) | GPR84KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL840394 | 0.78 | MAPT (0.50) | GPR84KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL14167604 | 0.77 | PIM1 (0.39) | GRM4 | |
| SCHEMBL30912114 | 0.74 | LIPE (0.41) | — | |
| SCHEMBL1888539 | 0.74 | LIPE (0.41) | — | |
| SCHEMBL20746102 | 0.72 | GPR84 (0.44) | GPR84GRM4 | |
| SCHEMBL20745696 | 0.71 | GPR84 (0.43) | GPR84GRM4 | |
| SCHEMBL20745662 | 0.71 | GPR84 (0.43) | GPR84GRM4 | |
| SCHEMBL20745659 | 0.71 | GPR84 (0.43) | GPR84GRM4 | |
| SCHEMBL24644841 | 0.70 | GPR84 (0.40) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3988555-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-111818917-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200325153-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2020-10-15 | — | — | US | disclosed |
| US-10676485-B2 | Macrocyclic MCL-1 inhibitors and methods of use | ABBVIE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3652184-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20190144465-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-16 | — | — | US | disclosed |
| WO-2019035911-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676485-B2 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | GPR84 4269/4885GRM4 4772/4885KDM4E 1725/4885 |
| US-20190144465-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | GPR84 4286/4885GRM4 4766/4885KDM4E 1519/4885 |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | GPR84 4269/4885GRM4 4772/4885KDM4E 1725/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | GPR84 4269/4885GRM4 4772/4885KDM4E 1725/4885 |
| US-20200325153-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | GPR84 4269/4885GRM4 4772/4885KDM4E 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.